Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders-Reference-Cited by-同舟云学术

Eptacog alfa activated: a recombinant product to treat rare congenital bleeding disorders

Published:2015-06 Issue: Volume:29 Page:S26-S33
ISSN:0268-960X
Container-title:Blood Reviews
language:en
Short-container-title:Blood Reviews

Author:

Minno Giovanni Di

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference46 articles.

1. Glanzmann's thrombasthenia (defective platelet integrin alphaIIb-beta3): proposals for management between evidence and open issues;Di Minno;Thromb Haemost,2009

2. Factor VII deficiency: defining the clinical picture and optimizing therapeutic options;Lapecorella;Haemophilia,2008

3. Treatment modalities and outcomes in 204 surgical procedures in 96 Glanzmann's thrombasthenia (GT) patients: the International Prospective Glanzmann's Thrombasthenia Registry (GTR);Poon;J Thromb Haemost,2013

4. Glanzmann's thrombasthenia treatment: a prospective observational registry on the use of recombinant human activated factor VII and other hemostatic agents;Poon;Semin Hematol,2006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spectrum of Causative Mutations in Patients with Hemophilia A in Russia;Genes;2023-01-19

2. Drugs with the highest drug expenditure in the Republic of Serbia;Hospital Pharmacology - International Multidisciplinary Journal;2023

3. KGML-xDTD: a knowledge graph–based machine learning framework for drug treatment prediction and mechanism description;GigaScience;2022-12-28

4. KGML-xDTD: A Knowledge Graph-based Machine Learning Framework for Drug Treatment Prediction and Mechanism Description;2022-12-02

5. Successful use of recombinant activated factor VII administered via automated bolus pump following emergency laparoscopic appendectomy in a patient with mild congenital FVII deficiency: Case report;Pediatric Blood & Cancer;2021-02-25